Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2026
INTERVENTION: CONDITION: Comparative bioavailability study under fasting conditions ; MedDRA version: 28.0Level: SOCClassification code: 10038359Term: Renal and urinary disorders Class: 18 Therapeutic area: Diseases [C] ‐ Cardiovascular Diseases [C14] PRIMARY OUTCOME: Main Objective: Primary end point(s): Secondary Objective: INCLUSION CRITERIA:
Epistemonikos ID: a2f0d7a65b8f0702ab493d0c072b19b69320e550
First added on: Apr 01, 2026